The ACTION study: methodology of a trial to evaluate safety and efficacy of a higher dose rivastigmine transdermal patch in severe Alzheimer's disease

References

• Novartis Pharma. Exelon Capsule Prescribing Information. 2001. Last accessed: September 2009. Available from: http://www.pharma.us.novartis.com/product/pi/pdf/exelon.pdf
   Google Scholar
• Novartis Pharma. Exelon transdermal patch Prescribing information. 2007. Last accessed: September 2009. Available from: http://www.pharma.us.novartis.com/product/pi/pdf/exelonpatch.pdf
   Google Scholar
• Darvesh S, Hopkins DA. Differential distribution of butyrylcholinesterase and acetylcholinesterase in the human thalamus. J Comp Neurol 2003;463:25-43
   PubMed Web of Science ®Google Scholar
• Lopez-Pousa S. Pilot, multicenter, randomized, double-blind, controlled, parallel efficacy and safety study of rivastigmine vs placebo in the treatment of cognitive and non-cognitive symptoms in patients with moderate-to-severe Alzheimer's disease. IFPMA Register 2005
   Google Scholar
• Winblad B, Grossberg G, Frolich L, et al. IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease. Neurology 2007;69:S14-22
   Web of Science ®Google Scholar
• Winblad B, Cummings J, Andreasen N, et al. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease – rivastigmine patch versus capsule. Int J Geriatr Psychiatry 2007;22:456-67
   PubMed Web of Science ®Google Scholar
• Galasko D, Bennett D, Sano M, et al. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997;11:S33-9
   Web of Science ®Google Scholar
• Galasko D, Schmitt F, Thomas R, et al. Detailed assessment of activities of daily living in moderate to severe Alzheimer's disease. J Int Neuropsychol Soc 2005;11:446-53
   PubMed Web of Science ®Google Scholar
• Panisset M, Roudier M, Saxton J, et al. Severe impairment battery. A neuropsychological test for severely demented patients. Arch Neurol 1994;51:41-5
   PubMed Web of Science ®Google Scholar
• Schneider LS, Olin JT, Doody RS, et al. Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997;11:S22-32
   Google Scholar
• Cummings JL, Mega M, Gray K, et al. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308-14
   PubMed Web of Science ®Google Scholar
• Forchetti CM. Treating patients with moderate to severe Alzheimer's disease: implications of recent pharmacologic studies. Prim Care Companion J Clin Psychiatry 2005;7:155-61
   PubMedGoogle Scholar
• Voisin T, Vellas B. Diagnosis and treatment of patients with severe Alzheimer's disease. Drugs Aging 2009;26:135-44
   PubMed Web of Science ®Google Scholar
• Herrmann N, Gauthier S. Diagnosis and treatment of dementia: 6. Management of severe Alzheimer disease. Can Med Assoc J 2008;179:1279-87
   Web of Science ®Google Scholar
• Hogan DB. Donepezil for severe Alzheimer's disease. Lancet 2006;367:1031-2
   PubMed Web of Science ®Google Scholar
• Winblad B, Kilander L, Eriksson S, et al. Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study. Lancet 2006;367:1057-65
   PubMed Web of Science ®Google Scholar
• Tariot PN, Farlow MR, Grossberg GT, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004;291:317-24
   PubMed Web of Science ®Google Scholar
• Lefevre G, Sedek G, Jhee S, et al. Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer's disease patients. Clin Pharmacol Ther 2008;83:106-14
   PubMed Web of Science ®Google Scholar
• Andersen CK, Wittrup-Jensen KU, Lolk A, et al. Ability to perform activities of daily living is the main factor affecting quality of life in patients with dementia. Health Qual Life Outcomes 2004;2:52
   PubMedGoogle Scholar
• Doody RS, Tariot PN, Pfeiffer E, et al. Meta-analysis of six-month memantine trials in Alzheimer's disease. Alzheimers Dement 2007;3:7-17
   PubMed Web of Science ®Google Scholar
• Kurz A, Farlow M, Quarg P, et al. Disease stage in Alzheimer disease and treatment effects of rivastigmine. Alzheimer Dis Assoc Disord 2004;18:123-8
   PubMed Web of Science ®Google Scholar
• Horner J, Alberts MJ, Dawson DV, et al. Swallowing in Alzheimer's disease. Alzheimer Dis Assoc Disord 1994;8:177-89
   PubMed Web of Science ®Google Scholar
• Suh MK, Kim H, Na DL. Dysphagia in patients with dementia: Alzheimer versus vascular. Alzheimer Dis Assoc Disord 2009;23:178-84
   PubMed Web of Science ®Google Scholar
• Bassil N, Grossberg GT. Novel regimens and delivery systems in the pharmacological treatment of Alzheimer's disease. CNS Drugs 2009;23:293-307
   PubMed Web of Science ®Google Scholar
• Blesa R, Ballard C, Orgogozo JM, et al. Caregiver preference for rivastigmine patches versus capsules for the treatment of Alzheimer disease. Neurology 2007;69:S23-8
   PubMed Web of Science ®Google Scholar
• Winblad B, Kawata AK, Beusterien KM, et al. Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease. Int J Geriatr Psychiatry 2007;22:485-91
   PubMed Web of Science ®Google Scholar
• Winblad B, Machado JC. Use of rivastigmine transdermal patch in the treatment of Alzheimer's disease. Expert Opin Drug Deliv 2008;5:1377-86
   PubMed Web of Science ®Google Scholar
• Small G, Dubois B. A review of compliance to treatment in Alzheimer's disease: potential benefits of a transdermal patch. Curr Med Res Opin 2007;23:2705-13
   PubMed Web of Science ®Google Scholar